Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
van den Bergh
Walter M
WM
Mees
Sanne M Dorhout
SM
Rinkel
Gabriel J E
GJ
D000328:Adult; D000368:Aged; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control*; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000627:therapeutic use; D002533:Cerebral Angiography; D002544:Cerebral Infarction / Q000453:epidemiology / Q000209:etiology / Q000401:mortality; D005260:Female; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D002532:Intracranial Aneurysm / Q000150:complications*; D008274:Magnesium / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009553:Nimodipine / Q000008:administration & dosage* / Q000627:therapeutic use; D010865:Pilot Projects; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome; D017585:Ultrasonography, Doppler, Transcranial; D020301:Vasospasm, Intracranial / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology
D002121:Calcium Channel Blockers; D009553:Nimodipine; D008274:Magnesium